BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:55:00 PM | Browse: 1096 | Download: 1998
 |
Received |
|
2013-01-18 08:38 |
|
Peer-Review Started |
|
2013-01-18 19:38 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2013-02-25 15:55 |
|
Revised |
|
|
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-04-28 14:29 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-04-29 01:10 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-06-04 17:41 |
|
Publish the Manuscript Online |
|
2013-06-20 16:34 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Microscopic colitis: A therapeutic challenge
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mario Guslandi |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mario Guslandi, MD, FACG, Professor, Gastroenterology Unit, S. Raffaele University Hospital, Via Olgettina 60, 20132 Milan, Italy. guslandi.mario@hsr.it |
| Key Words |
Microscopic colitis; Budesonide; Mesalazine; Immunosuppressants |
| Core Tip |
The efficacy of short-term treatment of microscopic colitis with budesonide is confirmed. Long-term therapy is not advisable because of possible side effects, but the efficacy of alternative drugs such as immunosuppressants or anti-tumor necrosis factor agents remains to be established. For the time being prolonged budesonide treatment in minimal doses, tailored on the single patient, appears to be the most sensible option. |
| Publish Date |
2013-06-20 16:34 |
| Citation |
Guslandi M. Microscopic colitis: A therapeutic challenge. World J Gastroenterol 2013; 19(23): 3531-3533 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i23/3531.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i23.3531 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
